• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Friday's Intraday Session

    3/31/23 1:31:13 PM ET
    $ANPC
    $BCLI
    $BDRX
    $BNOX
    Medical Specialities
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $ANPC alert in real time by email

    Gainers

    • Bionomics (NASDAQ:BNOX) shares moved upwards by 62.8% to $2.93 during Friday's regular session. The current volume of 285.9K shares is 236.1% of Bionomics's average full-day volume over the last 100 days (last updated at 13:30 EST). The company's market cap stands at $23.9 million.
    • Y-mAbs Therapeutics (NASDAQ:YMAB) shares increased by 53.49% to $5.05. As of 13:30 EST, this security is trading at a volume of 15.4 million shares, making up 4939.0% of its average full-day volume over the last 100 days. The company's market cap stands at $220.5 million. As per the press release, Q4 earnings came out yesterday.
    • Brainstorm Cell (NASDAQ:BCLI) shares increased by 35.79% to $3.4. Brainstorm Cell's stock is trading at a volume of 1.9 million shares as of 13:30 EST. This is 601.3% of its average full-day volume over the last 100 days. The company's market cap stands at $124.0 million. As per the press release, Q4 earnings came out yesterday.
    • Palisade Bio (NASDAQ:PALI) stock increased by 29.05% to $3.42. As of 13:30 EST, this security is trading at a volume of 29.0 million shares, making up 1080.9% of its average full-day volume over the last 100 days. The company's market cap stands at $15.4 million.
    • Pulse Biosciences (NASDAQ:PLSE) stock rose 29.02% to $3.2. The current volume of 248.0K shares is 487.3% of Pulse Biosciences's average full-day volume over the last 100 days (last updated at 13:30 EST). The company's market cap stands at $119.1 million. The company's, Q4 earnings came out yesterday.
    • Paratek Pharmaceuticals (NASDAQ:PRTK) stock rose 26.17% to $2.67. Trading volume for Paratek Pharmaceuticals's stock is 4.7 million as of 13:30 EST. This is 985.1% of its average full-day volume over the last 100 days. The company's market cap stands at $153.1 million.

    Losers

    • G Medical Innovations (NASDAQ:GMVD) shares decreased by 45.2% to $0.91 during Friday's regular session. As of 13:30 EST, this security is trading at a volume of 13.1 million shares, making up 1459.7% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $1.7 million.
    • Checkpoint Therapeutics (NASDAQ:CKPT) shares declined by 35.53% to $2.16. As of 13:30 EST, Checkpoint Therapeutics's stock is trading at a volume of 2.6 million, which is 1189.0% of its average full-day volume over the last 100 days. The company's market cap stands at $24.6 million. As per the news, the Q4 earnings report came out yesterday.
    • Pyxis Oncology (NASDAQ:PYXS) stock fell 25.51% to $4.47. Trading volume for this security as of 13:30 EST is 25.9 million, which is 959.5% of its average full-day volume over the last 100 days. The company's market cap stands at $165.3 million.
    • Biodexa Pharmaceuticals (NASDAQ:BDRX) stock fell 23.39% to $0.32. Trading volume for Biodexa Pharmaceuticals's stock is 5.1 million as of 13:30 EST. This is 40.9% of its average full-day volume over the last 100 days.
    • Cano Health (NYSE:CANO) stock declined by 23.3% to $0.87. Trading volume for this security as of 13:30 EST is 18.2 million, which is 226.1% of its average full-day volume over the last 100 days. The company's market cap stands at $228.9 million.
    • AnPac Bio-Medical Science (NASDAQ:ANPC) shares declined by 20.37% to $4.38. The current volume of 56.2K shares is 197.8% of AnPac Bio-Medical Science's average full-day volume over the last 100 days (last updated at 13:30 EST). The market value of their outstanding shares is at $8.9 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $ANPC alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ANPC
    $BCLI
    $BDRX
    $BNOX

    CompanyDatePrice TargetRatingAnalyst
    Palisade Bio Inc.
    $PALI
    2/25/2026$5.00Buy
    Stifel
    Pulse Biosciences Inc
    $PLSE
    1/30/2026$25.00Outperform
    Mizuho
    Palisade Bio Inc.
    $PALI
    1/9/2026$7.00Buy
    B. Riley Securities
    Palisade Bio Inc.
    $PALI
    12/29/2025$25.00Overweight
    Piper Sandler
    Pyxis Oncology Inc.
    $PYXS
    11/3/2025$9.00Buy
    Stifel
    Pyxis Oncology Inc.
    $PYXS
    9/4/2025$5.00Buy
    Guggenheim
    Pulse Biosciences Inc
    $PLSE
    7/7/2025$22.00Outperform
    Oppenheimer
    Y-mAbs Therapeutics Inc.
    $YMAB
    4/22/2025$3.00Neutral → Underperform
    BofA Securities
    More analyst ratings

    $ANPC
    $BCLI
    $BDRX
    $BNOX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Palisade Bio Announces Participation in Two Upcoming Investor Conferences

    Carlsbad, CA, March 02, 2026 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (NASDAQ:PALI) ("Palisade" or the "Company"), a clinical-stage biopharmaceutical company developing next-generation, once-daily, oral PDE4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon, today announced that management will participate in two upcoming investor conferences taking place during March 2026. Details are as follows: TD Cowen 46th Annual Health Care ConferenceDate/time: March 2, 2026 at 3:10 PM ESTLocation: Boston Mariott Copley Place, Boston, MAFormat: In-person presentation & investor meetingsWebcast link: Register here Investors registered to attend the conference who wish t

    3/2/26 9:00:00 AM ET
    $PALI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Brainstorm Cell Therapeutics Secures Second $1 Million Strategic Placement; Total $2 Million Raised In February

    NEW YORK, Feb. 26, 2026 /PRNewswire/ -- Brainstorm Cell Therapeutics Inc. (OTCQB: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, today announced it has entered into a second definitive agreement for an additional $1 million strategic private placement. This brings the total capital raised in February 2026 to $2 million. The financing is expected to reinforce a stable valuation for the company and provides the near-term resources required to advance its immediate regulatory and clinical objectives.Key Terms of the Second Placement:Market-Aligned Pricing: The common stock was priced at $0.60 per share, closely aligned with recent market performance (clo

    2/26/26 6:22:00 AM ET
    $BCLI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Palisade Bio Reports Rapid Clinical, Histologic and New Mechanistic Colon Tissue RNA Sequencing Data Supporting Targeted Activity of PALI-2108 at ECCO 2026

    Phase 1b translational data demonstrate localized ileocolonic target engagement, suppression of inflammatory and fibrotic gene programs, and early clinical response within seven days Encouraging safety profile across 89 subjects supports differentiated, colon-targeted PDE4 approach Translational analyses confirm local suppression of TNF-α, JAK–STAT, NF-κB, MAPK and TGF-β signaling in colon tissue with minimal peripheral immune modulation Data presented at the 21st Congress of the European Crohn's and Colitis Organization (ECCO) in Stockholm, Sweden Carlsbad, CA, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (NASDAQ:PALI) ("Palisade" or the "Company"), a clinical-stage biopharmac

    2/23/26 8:40:00 AM ET
    $PALI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ANPC
    $BCLI
    $BDRX
    $BNOX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Stifel initiated coverage on Palisade Bio with a new price target

    Stifel initiated coverage of Palisade Bio with a rating of Buy and set a new price target of $5.00

    2/25/26 7:53:12 AM ET
    $PALI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Mizuho initiated coverage on Pulse Biosciences with a new price target

    Mizuho initiated coverage of Pulse Biosciences with a rating of Outperform and set a new price target of $25.00

    1/30/26 6:44:12 AM ET
    $PLSE
    Medical/Dental Instruments
    Health Care

    B. Riley Securities initiated coverage on Palisade Bio with a new price target

    B. Riley Securities initiated coverage of Palisade Bio with a rating of Buy and set a new price target of $7.00

    1/9/26 9:07:04 AM ET
    $PALI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ANPC
    $BCLI
    $BDRX
    $BNOX
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for DANYELZA issued to Y-MABS THERAPEUTICS INC

    Submission status for Y-MABS THERAPEUTICS INC's drug DANYELZA (SUPPL-8) with active ingredient NAXITAMAB-GQGK has changed to 'Approval' on 03/20/2024. Application Category: BLA, Application Number: 761171, Application Classification:

    3/21/24 10:20:07 AM ET
    $YMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for NUZYRA issued to PARATEK PHARMS INC

    Submission status for PARATEK PHARMS INC's drug NUZYRA (SUPPL-10) with active ingredient OMADACYCLINE TOSYLATE has changed to 'Approval' on 05/27/2021. Application Category: NDA, Application Number: 209817, Application Classification: Efficacy

    5/31/21 5:18:25 AM ET
    $PRTK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for NUZYRA issued to PARATEK PHARMS INC

    Submission status for PARATEK PHARMS INC's drug NUZYRA (SUPPL-11) with active ingredient OMADACYCLINE TOSYLATE has changed to 'Approval' on 05/27/2021. Application Category: NDA, Application Number: 209816, Application Classification: Efficacy

    5/31/21 5:18:25 AM ET
    $PRTK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ANPC
    $BCLI
    $BDRX
    $BNOX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Williams Donald Allen bought $8,356 worth of shares (5,000 units at $1.67), increasing direct ownership by 87% to 10,728 units (SEC Form 4)

    4 - PALISADE BIO, INC. (0001357459) (Issuer)

    1/21/26 4:05:24 PM ET
    $PALI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Williams Donald Allen bought $9,400 worth of shares (5,000 units at $1.88), increasing direct ownership by 687% to 5,728 units (SEC Form 4)

    4 - PALISADE BIO, INC. (0001357459) (Issuer)

    1/13/26 9:43:07 PM ET
    $PALI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Duggan Robert W bought $2,788,624 worth of shares (192,599 units at $14.48), increasing direct ownership by 0.41% to 47,709,140 units (SEC Form 4)

    4 - PULSE BIOSCIENCES, INC. (0001625101) (Issuer)

    9/12/25 8:14:18 PM ET
    $PLSE
    Medical/Dental Instruments
    Health Care

    $ANPC
    $BCLI
    $BDRX
    $BNOX
    SEC Filings

    View All

    Pulse Biosciences Inc filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - PULSE BIOSCIENCES, INC. (0001625101) (Filer)

    3/3/26 4:34:48 PM ET
    $PLSE
    Medical/Dental Instruments
    Health Care

    Amendment: Pulse Biosciences Inc filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

    8-K/A - PULSE BIOSCIENCES, INC. (0001625101) (Filer)

    3/2/26 9:21:57 AM ET
    $PLSE
    Medical/Dental Instruments
    Health Care

    SEC Form EFFECT filed by Pulse Biosciences Inc

    EFFECT - PULSE BIOSCIENCES, INC. (0001625101) (Filer)

    3/2/26 12:15:20 AM ET
    $PLSE
    Medical/Dental Instruments
    Health Care

    $ANPC
    $BCLI
    $BDRX
    $BNOX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Commercial Officer Danahy Kevin Patrick exercised 5,000 shares at a strike of $1.53 and sold $118,200 worth of shares (5,000 units at $23.64) (SEC Form 4)

    4 - PULSE BIOSCIENCES, INC. (0001625101) (Issuer)

    2/23/26 8:55:39 PM ET
    $PLSE
    Medical/Dental Instruments
    Health Care

    Chief Commercial Officer Danahy Kevin Patrick exercised 60,000 shares at a strike of $1.53 and sold $1,410,600 worth of shares (60,000 units at $23.51) (SEC Form 4)

    4 - PULSE BIOSCIENCES, INC. (0001625101) (Issuer)

    2/17/26 8:47:42 PM ET
    $PLSE
    Medical/Dental Instruments
    Health Care

    Chief Medical Officer Jones Mitchell Lawrence converted options into 8,000 shares and sold $3,481 worth of shares (1,989 units at $1.75), increasing direct ownership by 83% to 13,263 units (SEC Form 4)

    4 - PALISADE BIO, INC. (0001357459) (Issuer)

    2/13/26 8:10:12 PM ET
    $PALI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ANPC
    $BCLI
    $BDRX
    $BNOX
    Leadership Updates

    Live Leadership Updates

    View All

    Palisade Bio Appoints Global IBD Precision Medicine Leader Bram Verstockt, MD, PhD to Clinical Advisory Board

    Appointment strengthens Phase 2 development strategy for PALI-2108 in ulcerative colitis and fibrostenotic Crohn's disease; Phase 2 ulcerative colitis IND submission planned for first half of 2026 Carlsbad, CA, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (NASDAQ:PALI) ("Palisade" or the "Company"), a clinical-stage biopharmaceutical company advancing next-generation, once-daily oral PDE4 inhibitor prodrugs engineered for targeted delivery to the terminal ileum and colon, today announced the appointment of Bram Verstockt, MD, PhD, to its Clinical Advisory Board (CAB). Dr. Verstockt is an internationally recognized expert in inflammatory bowel disease (IBD) and a leader in precisi

    2/17/26 8:45:00 AM ET
    $PALI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Pyxis Oncology Announces Interim CEO Appointment and Leadership Transition to Support Strategic Focus and Program Continuity

    BOSTON, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (NASDAQ:PYXS), a clinical-stage company developing next-generation therapeutics for difficult-to-treat cancers, today announced a leadership transition to continue execution and advancement of the Company's strategic and clinical goals. Thomas Civik, a member of Pyxis Oncology's Board of Directors since the Company's IPO and a highly experienced biotechnology executive with a proven track record in advancing cancer therapeutics, has been appointed Interim Chief Executive Officer, effective immediately. Lara S. Sullivan, M.D., has stepped down from her roles as President, Chief Executive Officer and Chief Medical Officer. With

    2/3/26 6:45:00 AM ET
    $PYXS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Palisade Bio Appoints Leading Global IBD Experts, Laurent Peyrin-Biroulet, MD, PhD and David T. Rubin, MD, to Its Clinical Advisory Board

    Internationally recognized leaders in inflammatory bowel disease bring deep expertise spanning ulcerative colitis, Crohn's disease, and late-stage clinical trial design Appointments strengthen Palisade Bio's clinical strategy as PALI-2108 advances toward Phase 2 development in ulcerative colitis and fibrostenotic Crohn's disease, with a Phase 2 UC IND submission planned for the first half of 2026 Carlsbad, CA, Jan. 29, 2026 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (NASDAQ:PALI) ("Palisade" or the "Company"), a clinical-stage biopharmaceutical company developing next-generation, once-daily, oral PDE4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon, today an

    1/29/26 8:45:00 AM ET
    $PALI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ANPC
    $BCLI
    $BDRX
    $BNOX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Biodexa Pharmaceuticals plc American Depositary Shs

    SC 13G/A - Biodexa Pharmaceuticals Plc (0001643918) (Subject)

    11/20/24 11:56:39 AM ET
    $BDRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Biodexa Pharmaceuticals plc American Depositary Shs

    SC 13G/A - Biodexa Pharmaceuticals Plc (0001643918) (Subject)

    11/14/24 5:12:47 PM ET
    $BDRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Checkpoint Therapeutics Inc.

    SC 13G/A - Checkpoint Therapeutics, Inc. (0001651407) (Subject)

    11/14/24 4:49:25 PM ET
    $CKPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ANPC
    $BCLI
    $BDRX
    $BNOX
    Financials

    Live finance-specific insights

    View All

    Pulse Biosciences Reports Business Updates and Fourth Quarter & Full Year 2025 Financial Results

    Pulse Biosciences, Inc. (NASDAQ:PLSE), developer of the novel nPulse™ technology using proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) energy, today announced business updates and financial results for the fourth quarter and full year ended December 31, 2025. Recent Business Highlights Endocardial Catheter AF Ablation Highlighted 100% procedural success, or freedom from atrial fibrillation (AF), at 6 months and 96% procedural success at one year, of evaluable patients, following treatments with the nPulse Cardiac Catheter System in the first-in-human feasibility study which was presented as late-breaking data at the 31st Annual AF Symposium Meeting. Receiv

    2/19/26 4:05:00 PM ET
    $PLSE
    Medical/Dental Instruments
    Health Care

    Pulse Biosciences Schedules Fourth Quarter & Full Year 2025 Financial Results Conference Call for February 19, 2026

    Pulse Biosciences, Inc. (NASDAQ:PLSE), a company leveraging its novel nPulse™ technology using its proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) energy, today announced it will report business updates and financial results for the fourth quarter and full year 2025 after market close on Thursday, February 19, 2026. Company management will host a corresponding conference call beginning at 1:30pm PT / 4:30pm ET. Investors interested in listening to the conference call may do so by dialing 1-800-715-9871 from the U.S. or 1-646-307-1963 internationally and providing Conference ID 7647402. A live and recorded webcast of the event will be available on the Pulse Bioscie

    2/4/26 4:05:00 PM ET
    $PLSE
    Medical/Dental Instruments
    Health Care

    Pyxis Oncology Announces Positive Preliminary Phase 1 Data for Micvotabart Pelidotin (MICVO) in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

    46% confirmed objective response rate (ORR) and 92% disease control rate (DCR) observed with MICVO as monotherapy in 2L+ R/M HNSCC at 5.4 mg/kg 71% confirmed ORR and 100% DCR observed with MICVO in combination with KEYTRUDA® (pembrolizumab) in 1L/2L+ R/M HNSCC at 3.6 mg/kg and 4.4 mg/kgUpdated data from ongoing Phase 1 monotherapy study in 2L+ R/M HNSCC expected mid-2026; updated data from ongoing Phase 1/2 study evaluating MICVO in combination with KEYTRUDA®, including in 1L/2L+ R/M HNSCC and other tumor types, expected 2H26 Company to host webcast and conference call today at 8:30 a.m. ET BOSTON, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (NASDAQ:PYXS), a clinical-stage comp

    12/18/25 7:00:00 AM ET
    $PYXS
    Biotechnology: Pharmaceutical Preparations
    Health Care